Get started
Author

Peter Kok-Ting Wan

Observed name: P Kok-Ting Wan
ORCID: 0000-0003-0414-5453
Observed ORCID: 0000-0003-0414-5453
OpenAlex ID: A5076745657
T cell engagers: expanding horizons in oncology and beyond
2025 · Gulsah Albayrak, Peter Kok-Ting Wan, et al. · British Journal of Cancer · 89
PDF
Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus
2021 · Peter Kok-Ting Wan, Anderson J. Ryan, et al. · Molecular Therapy · 69
PDF
CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma
2020 · Xue-Tang Mo, Thomas Ho-Yin Leung, et al. · British Journal of Cancer · 43
PDF
HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer
2020 · Peter Kok-Ting Wan, Thomas Ho-Yin Leung, et al. · Cancer Letters · 32
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells
2024 · Richard Baugh, Hena Khalique, et al. · Journal for ImmunoTherapy of Cancer · 31
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
2023 · Peter Kok-Ting Wan, Ricardo A Fernandes, et al. · Journal for ImmunoTherapy of Cancer · 23
PDF
Role of Nurr1 in Carcinogenesis and Tumor Immunology: A State of the Art Review
2020 · Peter Kok-Ting Wan, Michelle Kwan-Yee Siu, et al. · Cancers · 13
PDF
Evidence of endothelial anergy and T-cell exclusion in microsatellite stable colorectal liver metastases revealed through human hemi-liver perfusion and spatial transcriptomics
2026 · Peter Kok-Ting Wan, Ranchu Cheng, et al. · Molecular Cancer · 1
OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study
2026 · Peter Kok-Ting Wan, Thomas Morris, et al. · medRxiv
Therapeutic HPV16 E7 vaccination with CD137 agonism induces tumor regression and durable immunity in mice
2026 · Yuqian Ou, Wenshu Lu, et al. · iScience
PDF
Additional file 2 of Evidence of endothelial anergy and T-cell exclusion in microsatellite stable colorectal liver metastases revealed through human hemi-liver perfusion and spatial transcriptomics
2026 · Peter Kok-Ting Wan, Ranchu Cheng, et al. · Figshare
Additional file 3 of Evidence of endothelial anergy and T-cell exclusion in microsatellite stable colorectal liver metastases revealed through human hemi-liver perfusion and spatial transcriptomics
2026 · Peter Kok-Ting Wan, Ranchu Cheng, et al. · Figshare
Additional file 1 of Evidence of endothelial anergy and T-cell exclusion in microsatellite stable colorectal liver metastases revealed through human hemi-liver perfusion and spatial transcriptomics
2026 · Peter Kok-Ting Wan, Ranchu Cheng, et al. · Figshare
Abstract 6203: Spatial transcriptome mapping identifies endothelial anergy and CD4+ T cell stress as key drivers of immune escape in colorectal cancer liver metastasis
2026 · Peter Kok-Ting Wan, Ranchu Cheng, et al. · Cancer Research
Lipid-rich ascites reprograms T cell lipid metabolic transcriptome to drive dysfunction
2026 · Peter Kok-Ting Wan, Gulsah Albayrak, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
S65 Evaluation of protein X-targeting bispecific T cell engager therapy in patient-derived mesothelioma cell cultures
2025 · N Manoharan, P Kok-Ting Wan, et al. · Thorax
Works count: 16
Citation count: 301
H-index: 7
I10-index: 7
Year
Topic
Type